Core Viewpoint - Kenvue Inc. is a leading consumer health company with a market cap of $27.5 billion, managing trusted brands like Tylenol and Neutrogena, but has significantly underperformed the market over the past year [1][2]. Performance Summary - Kenvue's shares have declined 37.8% over the past 52 weeks, while the S&P 500 Index has gained 17.4%. Year-to-date, the stock is down 33.3%, compared to a 16% rise in the S&P 500 [2][4]. - The company has also lagged behind the Consumer Staples Select Sector SPDR Fund, which saw a 4.7% drop over the past year and a 2.7% decline year-to-date [3]. Earnings Report - In Q2, Kenvue reported a 4% year-over-year decline in net sales to $3.8 billion, missing consensus estimates, driven by a 4.2% decline in organic sales across all segments. Adjusted EPS was $0.29, down 9.4% from the previous year but slightly above analyst expectations [4]. - For the current fiscal year ending in December, analysts expect Kenvue's EPS to decline 13.2% year-over-year to $0.99. The company has a promising earnings surprise history, having met or exceeded consensus estimates in the last four quarters [5]. Analyst Ratings and Price Targets - Among 16 analysts covering Kenvue, the consensus rating is a "Moderate Buy," with five "Strong Buy," ten "Hold," and one "Strong Sell" rating [5]. - Canaccord Genuity recently lowered its rating to "Hold" and cut its price target to $15, indicating a 5.3% potential upside. The mean price target of $19.29 suggests a 35.5% premium, while the highest target of $23 indicates a potential upside of 61.5% [6].

Group 1 - Kenvue Inc. (NYSE:KVUE) is identified as one of the 10 Stocks Under $20 to Buy according to analysts [1] - Jefferies has reduced its price target for Kenvue from $25 to $23, citing signs of weakness in retail trends, with a 1.5% drop representing a 100 basis point reduction quarter-over-quarter [1][2] - Deutsche Bank also lowered its price target from $20 to $18 while maintaining a Hold rating [3] Group 2 - Jefferies believes that Kenvue's guidance for 2025 will remain intact despite the lowered price target due to liability risks [2] - The company is facing legal challenges in the UK related to allegations that its talc products cause cancer [1] - Kenvue Inc. is a global consumer health company with well-known brands such as Aveeno, BAND-AID, Johnson's, Listerine, Neutrogena, and Tylenol [3]

Group 1 - Kenvue Inc. (NYSE:KVUE) is considered a promising stock, but recent macroeconomic challenges have led to lowered price targets by analysts [1][3] - Jefferies analyst Keith Devas reduced Kenvue's price target from $25 to $23 while maintaining a Buy rating, citing impacts on consumer health stocks [1] - Deutsche Bank analyst Stephen Powers also lowered Kenvue's price target from $20 to $18, assigning a Hold rating [2] Group 2 - Kenvue operates as a consumer health company across multiple regions, including the US, Europe, the Middle East, Africa, Asia-Pacific, and Latin America [4] - The company has three operational segments: Self Care, Skin Health and Beauty, and Essential Health [4] - Jeff Smith, a board member and CEO of Starboard Value, indicated that Kenvue is focused on maximizing shareholder value through collaboration between management and the board [3]

Group 1 - The article discusses Kenvue (KVUE), the former consumer health division of Johnson & Johnson (JNJ), and rates the stock a "sell" due to strong overvaluation and expectations of limited risks with decent to high upside [1] - The analysis emphasizes the importance of identifying undervalued stocks while focusing on risk and reward, suggesting that the best investment ideas are often the simplest and contrarian approaches may yield better results [1]

Group 1 - Kenvue Inc. (NYSE:KVUE) is considered a stock with significant upside potential despite recent price target reductions by major banks [1][2] - Deutsche Bank lowered its price target for Kenvue to $18 from $20 while maintaining a Hold rating [1][2] - JPMorgan also reduced its price target for Kenvue to $21 from $24, keeping an Overweight rating, citing a weak outlook for large-cap companies in the household and personal care sector [1][2] Group 2 - The consumer health company operates in multiple regions including the US, Europe, the Middle East, Africa, Asia-Pacific, and Latin America [3] - Kenvue's business segments include Self Care, Skin Health & Beauty, and Essential Health [3]

Core Insights - Analysts identify nine S&P 500 stocks that have declined 30% or more this year, including Moderna and Kenvue, which are expected to rally by 30% or more in the next 12 months [1][6]. Group 1: Market Performance - The S&P 500 has increased by 35% since its year-to-date low on April 8, 2025, and has risen over 92% since the bull market began on October 12, 2022, excluding dividends [2]. - Analysts are searching for stocks that have not yet fully participated in the current market rally [2]. Group 2: Company-Specific Analysis - Moderna's stock has dropped nearly 40% this year, with an expected earnings per share (EPS) decline of 4% [3]. - Despite the negative sentiment, analysts project a 59% upside for Moderna, targeting a price of 40.30 in 12 months [4]. - Kenvue's stock is down 32% this year, but analysts anticipate an 8% EPS increase in 2026, with a target price of 20.37, representing a 40.4% gain [4]. Group 3: Promising Stocks - The following "left out" S&P 500 stocks are expected to recover significantly: - Moderna (MRNA): YTD change -39.0%, 12-month upside 59.0% [6] - Alexandria Real Estate Equities (ARE): YTD change -35.5%, 12-month upside 52.6% [6] - GoDaddy (GDDY): YTD change -33.7%, 12-month upside 44.4% [6] - Kenvue (KVUE): YTD change -32.0%, 12-month upside 40.4% [6] - Fiserv (FI): YTD change -38.6%, 12-month upside 34.7% [6] - The Trade Desk (TTD): YTD change -56.0%, 12-month upside 34.6% [6] - Align Technology (ALGN): YTD change -36.1%, 12-month upside 31.5% [6] - Chipotle Mexican Grill (CMG): YTD change -33.2%, 12-month upside 31.4% [6] - Oneok (OKE): YTD change -31.2%, 12-month upside 31.3% [6]

Group 1 - SNAP will suspend federal food aid from November 1 due to the government shutdown, affecting millions of Americans [3] - Kenvue has appointed a new chief marketing officer amid legal challenges regarding Tylenol marketing related to autism risk [3] - Melissa, a Category 5 hurricane, made landfall in Jamaica and may impact the hotel sector [4] Group 2 - The Federal Reserve is expected to reduce its key rate by 25 basis points to a range of 3.75%-4.00% during the upcoming meeting [5] - Policymakers are entering the meeting without key economic data due to the government shutdown, including nonfarm payrolls and the core PCE index [6] - Wall Street strategists anticipate the Fed may signal an end to balance sheet reduction by year-end as reserves approach "ample" levels [7] Group 3 - Seeking Alpha sentiment shows mixed expectations among subscribers regarding the number of Fed cuts before year-end, with 50% forecasting one cut and 44% expecting two more in 2025 [8] - Cameco and Brookfield are partnering with the U.S. for an $80 billion nuclear initiative [9] - Microsoft and OpenAI's collaboration is expected to accelerate AI advancements [9]

Core Viewpoint - Texas Attorney General Ken Paxton has filed a lawsuit against Johnson & Johnson and Kenvue, alleging that they knowingly concealed Tylenol's links to autism and ADHD, following unproven claims made by former President Donald Trump regarding the drug's safety during pregnancy [1][2]. Company Overview - Johnson & Johnson has been selling Tylenol for over 60 years, while Kenvue, which was spun off from Johnson & Johnson, has been selling the product since 2023 [2]. - Kenvue has consistently defended the safety of Tylenol, asserting that it is the safest pain reliever option for pregnant women [3]. Legal Context - The lawsuit comes five weeks after Donald Trump's controversial statement linking Tylenol use during pregnancy to autism, which lacks scientific backing [1]. - Johnson & Johnson has stated that Kenvue is responsible for all rights and liabilities associated with the sale of its over-the-counter products, including Tylenol [3].

Texas Attorney General announced a lawsuit against Johnson & Johnson and Kenvue, alleging the companies deceptively marketed their Tylenol drug to pregnant mothers. https://t.co/tRjaSOgAW5 (Photo: Justin Sullivan via Getty Images) https://t.co/0o5srHdwPS ...

Core Viewpoint - Texas Attorney General Ken Paxton is suing Kenvue and Johnson & Johnson for allegedly misleading marketing of Tylenol to pregnant women, despite known risks of autism and other disorders associated with its active ingredient, acetaminophen [1][2]. Company Actions and Responses - Kenvue and Johnson & Johnson are facing legal action for their marketing practices regarding Tylenol, with claims that they were aware of the potential risks linked to acetaminophen [2][3]. - Kenvue asserts that acetaminophen is the safest pain relief option for pregnant women and emphasizes the importance of consulting healthcare professionals before taking any medication [6][7]. - Johnson & Johnson stated that it divested its consumer health business years ago, transferring all rights and liabilities related to Tylenol to Kenvue [10]. Market Impact - Following the announcement of the lawsuit and the claims linking Tylenol to autism, shares of Kenvue and Johnson & Johnson experienced declines, with Kenvue's shares dropping by 2.02% and Johnson & Johnson's by 0.73% [11]. Public Statements and Controversies - Paxton criticized the pharmaceutical industry for prioritizing profits over public health, claiming that companies have endangered millions [3]. - The claims regarding Tylenol's association with autism have been met with skepticism from the medical community, which maintains that acetaminophen is safe for use during pregnancy [11]. - The announcement by President Trump and HHS Secretary Robert F. Kennedy linking Tylenol to autism has been criticized as misleading and harmful by organizations like the Autism Society of America [14][15].